FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2972028269> ?p ?o ?g. }

• W2972028269 abstract "Background: It has not been yet adequately addressed whether the addition of the nonstatin LDL-C (low-density lipoprotein cholesterol)-lowering agents on top of statins has the same magnitude of risk reduction in the cardiovascular events as compared with more-intensive statin therapy. Methods and Results: We performed a systematic review and meta-analysis of RCTs (randomized controlled trials) comparing more- versus less-intensive lipid-lowering therapy (LLT) on clinical outcomes in patients with atherosclerotic cardiovascular risk. We included 23 studies involving 133 037 patients (more-intensive LLT: 67 691 patients and less-intensive LLT: 65 346 patients). We evaluated 3 types of more- versus less-intensive LLT including more versus less statins (57 672 patients), combination therapy of ezetimibe versus statins alone (20 688 patients), or a PCSK9 (proprotein convertase subtilisin-kexin type 9) inhibitor with statins versus statins alone (54 677 patients). The odds for major adverse cardiovascular events (MACE; equivalent to the composite of coronary heart death, nonfatal myocardial infarction, stroke, or coronary revascularization) were significantly lower in the more-intensive LLT group compared with the less-intensive LLT group in the entire study population (odds ratio, 0.84; 95% CI, 0.79–0.88; P <0.001), and in all the 3 categories of more-intensive LLT strategies (more-intensive statin therapy: odds ratio, 0.83; 95% CI, 0.76–0.90; P <0.001, ezetimibe: odds ratio, 0.90; 95% CI, 0.85–0.96; P <0.001, and PCSK9 inhibitors: odds ratio, 0.81; 95% CI, 0.73–0.90; P <0.001) with numerically greater relative odds reduction by more-intensive statin therapy and PCSK9 inhibitors than by ezetimibe. Odds reduction for MACE per 20 mg/dL LDL-C reduction was also different across the 3 types of more-intensive LLT (more-intensive statin therapy: 17.4%, ezetimibe: 11.0%, and PCSK9 inhibitors: 6.6%). Conclusions: In this meta-analysis, more-intensive LLT as compared with less-intensive LLT was associated with significant odds reduction for MACE in the entire study population and in all the 3 categories of more-intensive LLT such as more-intensive statin therapy, ezetimibe, and PCSK9 inhibitors. However, overall odds reduction for MACE and odds reduction for MACE per 20 mg/dL LDL-C reduction were different across the 3 types of more-intensive LLT. Registration: URLs: https://www.crd.york.ac.uk/PROSPERO/ and http://www.umin.ac.jp/ctr . Unique identifiers: PROSPERO: CRD42018081196, and UMIN-CTR: R000036229." @default.
• W2972028269 created "2019-09-12" @default.
• W2972028269 creator A5005311216 @default.
• W2972028269 creator A5015228576 @default.
• W2972028269 creator A5015604127 @default.
• W2972028269 creator A5019825512 @default.
• W2972028269 creator A5033861263 @default.
• W2972028269 creator A5036299282 @default.
• W2972028269 creator A5042023852 @default.
• W2972028269 creator A5043428080 @default.
• W2972028269 creator A5066001703 @default.
• W2972028269 creator A5080185082 @default.
• W2972028269 creator A5090316816 @default.
• W2972028269 date "2019-08-01" @default.
• W2972028269 modified "2023-10-16" @default.
• W2972028269 title "More- Versus Less-Intensive Lipid-Lowering Therapy" @default.
• W2972028269 cites W1520609538 @default.
• W2972028269 cites W199262836 @default.
• W2972028269 cites W2001328643 @default.
• W2972028269 cites W2019071303 @default.
• W2972028269 cites W2041455142 @default.
• W2972028269 cites W2069518960 @default.
• W2972028269 cites W2071154679 @default.
• W2972028269 cites W2076279984 @default.
• W2972028269 cites W2100800328 @default.
• W2972028269 cites W2111099202 @default.
• W2972028269 cites W2120289695 @default.
• W2972028269 cites W2125435699 @default.
• W2972028269 cites W2139168645 @default.
• W2972028269 cites W2153043827 @default.
• W2972028269 cites W2159449551 @default.
• W2972028269 cites W2164089346 @default.
• W2972028269 cites W2169523655 @default.
• W2972028269 cites W2324839838 @default.
• W2972028269 cites W2331310316 @default.
• W2972028269 cites W2342318753 @default.
• W2972028269 cites W2465758073 @default.
• W2972028269 cites W2473272179 @default.
• W2972028269 cites W2519634482 @default.
• W2972028269 cites W2552951299 @default.
• W2972028269 cites W2571086022 @default.
• W2972028269 cites W2596179513 @default.
• W2972028269 cites W2766784925 @default.
• W2972028269 cites W2773258653 @default.
• W2972028269 cites W2801100099 @default.
• W2972028269 cites W2804251795 @default.
• W2972028269 cites W2899997727 @default.
• W2972028269 cites W4211152466 @default.
• W2972028269 cites W4236673002 @default.
• W2972028269 doi "https://doi.org/10.1161/circoutcomes.118.005460" @default.
• W2972028269 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/31412729" @default.
• W2972028269 hasPublicationYear "2019" @default.
• W2972028269 type Work @default.
• W2972028269 sameAs 2972028269 @default.
• W2972028269 citedByCount "7" @default.
• W2972028269 countsByYear W29720282692019 @default.
• W2972028269 countsByYear W29720282692021 @default.
• W2972028269 countsByYear W29720282692022 @default.
• W2972028269 countsByYear W29720282692023 @default.
• W2972028269 crossrefType "journal-article" @default.
• W2972028269 hasAuthorship W2972028269A5005311216 @default.
• W2972028269 hasAuthorship W2972028269A5015228576 @default.
• W2972028269 hasAuthorship W2972028269A5015604127 @default.
• W2972028269 hasAuthorship W2972028269A5019825512 @default.
• W2972028269 hasAuthorship W2972028269A5033861263 @default.
• W2972028269 hasAuthorship W2972028269A5036299282 @default.
• W2972028269 hasAuthorship W2972028269A5042023852 @default.
• W2972028269 hasAuthorship W2972028269A5043428080 @default.
• W2972028269 hasAuthorship W2972028269A5066001703 @default.
• W2972028269 hasAuthorship W2972028269A5080185082 @default.
• W2972028269 hasAuthorship W2972028269A5090316816 @default.
• W2972028269 hasBestOaLocation W29720282691 @default.
• W2972028269 hasConcept C126322002 @default.
• W2972028269 hasConcept C156957248 @default.
• W2972028269 hasConcept C164705383 @default.
• W2972028269 hasConcept C168563851 @default.
• W2972028269 hasConcept C177713679 @default.
• W2972028269 hasConcept C2776839432 @default.
• W2972028269 hasConcept C2778163477 @default.
• W2972028269 hasConcept C2778657065 @default.
• W2972028269 hasConcept C2780072125 @default.
• W2972028269 hasConcept C2780948078 @default.
• W2972028269 hasConcept C2908647359 @default.
• W2972028269 hasConcept C2987404301 @default.
• W2972028269 hasConcept C43554185 @default.
• W2972028269 hasConcept C500558357 @default.
• W2972028269 hasConcept C71924100 @default.
• W2972028269 hasConcept C90924648 @default.
• W2972028269 hasConcept C99454951 @default.
• W2972028269 hasConceptScore W2972028269C126322002 @default.
• W2972028269 hasConceptScore W2972028269C156957248 @default.
• W2972028269 hasConceptScore W2972028269C164705383 @default.
• W2972028269 hasConceptScore W2972028269C168563851 @default.
• W2972028269 hasConceptScore W2972028269C177713679 @default.
• W2972028269 hasConceptScore W2972028269C2776839432 @default.
• W2972028269 hasConceptScore W2972028269C2778163477 @default.
• W2972028269 hasConceptScore W2972028269C2778657065 @default.
• W2972028269 hasConceptScore W2972028269C2780072125 @default.
• W2972028269 hasConceptScore W2972028269C2780948078 @default.
• W2972028269 hasConceptScore W2972028269C2908647359 @default.

• next